Rival targeted therapies take aim at bladder cancer

4 October 2019

As the dust settles on 2019’s annual meeting of the European Society of Medical Oncology (ESMO), data from several candidates give hope that the burden of disease may soon be alleviated for millions of people diagnosed with bladder cancer.

In the USA alone, around 80,000 adults, mainly older people and mainly men, are diagnosed with this form of cancer - making it the fourth most common type. It is also the eighth most deadly form of cancer, causing an estimated 17,000 deaths annually.

While the overall five-year survival rate is currently 77%, and the overall 10-year survival rate is 70%, the impact of disease can be high, with many people having to undergo a cystectomy to remove the bladder.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK